<DOC>
	<DOCNO>NCT02673970</DOCNO>
	<brief_summary>1 . Screen recruitment : patient screen base prior history intention initiate treatment immune checkpoint inhibitor . 2 . Study phase : - Collection baseline demographic data , prior disease history , nature ICI therapy , outcome data ICI therapy ( treatment disposition , toxicity , tumor response survival ) . - Collection blood sample perform every 3 4 week first year ICI therapy every 6 12 week thereafter end ICI therapy , disease progression , death loss follow-up . Collection blood sample align visit necessary administration ICI therapy . - Collection archival melanoma metastasis tissue perform continuous basis trigger availability tissue follow therapeutic resection melanoma metastasis . 3 . Follow-up phase</brief_summary>
	<brief_title>Biomarkers Activity Immune Checkpoint Inhibitor Therapy Patients With Advanced Melanoma</brief_title>
	<detailed_description>1 . Screen recruitment : patient screen base prior history intention initiate treatment immune checkpoint inhibitor . This screening candidate patient investigator non-interventional . Patients consider eligible candidate invite participate study Page 3/18 provide write informed consent . 2 . Study phase : - Collection baseline demographic data , prior disease history , nature ICI therapy , outcome data ICI therapy ( treatment disposition , toxicity , tumor response survival ) . - Collection blood sample perform every 3 4 week first year ICI therapy every 6 12 week thereafter end ICI therapy , disease progression , death loss follow-up . Collection blood sample align visit necessary administration ICI therapy . - Collection archival melanoma metastasis tissue perform continuous basis trigger availability tissue follow therapeutic resection melanoma metastasis . 3 . Follow-up phase : patient stop treatment immune checkpoint inhibitor followed-up</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Histologically confirm malignant melanoma ; 2 . AJCC Stage IIIC IV melanoma evaluable disease ; 3 . Treatment immune checkpoint inhibitor ; 4 . Willing able give write informed consent ; 5 . Accessible treatment followup ; non</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Melanoma</keyword>
</DOC>